Harvard's KinoPlex cuts 1.8 million phosphorylation sites down to 250,000 plausible ones

A Harvard Medical School team has published KinoPlex in Nature Biotechnology, an AI-enabled structural atlas that maps the three-dimensional structure and biochemical environment of all 1.8 million sites on human proteins where a kinase might act, and matches those sites to the kinases capable of hitting them ^{[1] [2] [3]}. That matters because researchers have fully characterized fewer than 1% of those sites, which is why picking among kinase inhibitors has been closer to informed guessing than to lookup ^[4].

The biology sets the problem size. There are roughly 500 human kinases, each with different requirements for its binding sites ^[5]. Earlier work, much of it led by corresponding author Lewis Cantley of HMS and Dana-Farber, characterized the biochemical signatures at those sites to infer which kinase could be a match ^[6]. KinoPlex is the first approach to also fold in the 3D structure of the region, measuring more than 100 properties around each candidate site ^{[7] [8]}.

The structural layer is the load-bearing result, and it is a subtractive one. In many cases, according to the team, a site carries the right amino acid sequence but is physically inaccessible to the matching kinase ^[9]. After filtering for both a recognizable biochemical signature and a compatible 3D shape, roughly 250,000 sites survive ^[10], about 14% of the 1.8 million ^[21]. That is still more than an order of magnitude beyond the fewer than 18,000 sites previously characterized in full ^[22], but these are predictions, not confirmations.

The clinical pitch runs through a scoring framework that converts detected phosphorylation sites into measurements of kinase activity ^[11]. Tested on leukemia cells, it identified kinase signals associated with the cancer's growth and survival ^[12]. Across additional cell lines and multiple cancer types, the team says it identified which signaling pathways mattered most to each cell and which kinase inhibitors might therefore work ^[13]. The addressable drug list is real: around 100 existing kinase-inhibiting treatments, of which more than 90 are FDA-approved, per senior author Steven Gygi ^{[14] [15]}.

Everything past that point is conditional. The paper's own framing is that the tool could help doctors match patients to drugs if validated in the clinic ^[14]. Gygi says that by analyzing a patient's mutations and phosphorylation state, the team "might be able to predict which drugs would provide the best therapeutic effect" ^[17]. Validation is now the work: the researchers are partnering with oncologists at Brigham and Women's Hospital and Massachusetts General Hospital to test KinoPlex on clinical samples from cancer patients ^[16].

Diagnostics teams should read Gygi's own description of the assay class carefully. He calls it very different from existing diagnostics, "a signature of a process, not just a level of a protein or something similar" ^[18]. A process signature is a harder analytical validation than a threshold on one analyte, because the input is a phosphoproteomic measurement whose reproducibility across sites and sample handling becomes part of the claim.

What to watch: whether the hospital collaborations report concordance between KinoPlex-called kinase activity and known drivers in the same tumors, and then whether the score ranks drugs in a way that survives blinded or prospective testing. No timeline, endpoint, or sample count has been disclosed for that work ^[16]. Meanwhile the tool is public, released with help from Cell Signaling Technology ^[19], and first author David Vanderwall says anyone can start applying it ^[20]. Cheap for a lab to try is not the same as fit for a clinic.